Source: Assure Holdings Corp.
  • Assure Holdings (IOM) has closed its private placement for gross proceeds of US$4.75 million
  • The company issued approximately 900,000 shares at a price of $5.25 per share
  • Assure management and the board of directors anticipate participating in a subsequent private placement, for aggregate gross proceeds of up to US$700,000
  • Assure Holdings provides neurosurgeons and orthopedic spine surgeons a suite of services that support intraoperative neuromonitoring activities during invasive surgeries
  • Assure Holdings Corp. (IOM) opened trading at C$6.65 per share

Assure Holdings (IOM) has closed its private placement for gross proceeds of US$4.75 million.

The company issued approximately 900,000 shares at a price of $5.25 per share.

Proceeds will be deployed to service the system-wide contract with Premier, Inc., expand the company’s high-margin remote neurology platform and for general corporate purposes.

Assure management and the board of directors anticipate participating in a subsequent private placement, for aggregate gross proceeds of up to US$700,000.

Kestrel Merchant Partners LLC acted as the exclusive sponsor and The Benchmark Company, LLC acted as sole placement agent in connection with the offering. The company has agreed to pay the Agent a cash commission representing approximately 7 per cent of the gross proceeds of the offering.

Assure Holdings is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a suite of services that support intraoperative neuromonitoring activities during invasive surgeries.

Assure Holdings Corp. (IOM) opened trading at C$6.65 per share.

More From The Market Online

Telo Genomics and Emery Pharma collaborate

Telo Genomics (TSXV:TELO) collaborates with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.